To determine whether c-fms inhibition has therapeutic potential for chronic AAN, we performed an intervention study with fms-I versus vehicle treatment over days 14 to 28 and compared this to untreated (UT) AAN. The gene discussed is CSF1R; the disease is Balkan nephropathy.